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of 0.5 (95%CI: 0.3-0.8) for DRSP/estradiol vs. other occHRT. ConClusions: Results 
indicate a good safety profile with respect to cardiovascular risk for DRSP/estra-
diol. Serious cardiovascular events occur less frequently in DRSP/estradiol users 
compared to users of other continuous-combined HRT. This specificAS approach 
proved to be a successful approach with high long term follow-up success and 
high validity of safety results.
IndIvIdual’s HealtH – Cost studies
PIH7
Budget ImPaCt of HPv16/18 genotyPIng tests for tHe management of 
non-ConCordant CotestIng CervICal CanCer sCreenIng results: a 
unIted states Payer PersPeCtIve
Huang J.1, Hertz D.2, Conner A.2, Garfield S.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Bridgehead, Wayland, MA, USA
objeCtives: To assess the impact of managing women with high-risk HPV positive 
and Pap negative results (hrHPV+/Pap-) attending cervical cancer (CxCa) screening 
with a Pap and HPV test (co-testing). The strategies tested reflect different options 
available if a hrHPV test versus a hrHPV including 16/18 genotyping (3-in-1 test) 
is used upon initial screen. Methods: A budget-impact model was developed, 
from a US payer perspective. Data from the ATHENA (Addressing THE Need for 
Advanced HPV Diagnostics) trial and published literature were used to populate 
the model. The scenarios tested include repeat co-testing in 12 months, reflex 
genotyping HPV16/18, or routine co-testing with genotyping results already avail-
able from a 3-in-1 test for triage to colposcopy. The model examined the annual 
cost of testing and treatment for cervical intraepithelial neoplasia grade 2 or worse 
(≥ CIN2) and the cost of patients loss-to-follow-up. For a hypothetical population 
of women between ages 30 to 69, it assumes 48.5% were co-tested within the CxCa 
screening program every 3 years. Of those, 6.7% of women receive hrHPV+/Pap- 
results. Test performance was modeled as equivalent for both genotyping sce-
narios. Results: In the hrHPV+/Pap- population, the cost of ≥ CIN2 cases detected 
and treated for each testing strategy and the rate of progression to invasive CxCa 
per 10,000 hrHPV+/Pap- results was $10,530/9.2 (repeat co-testing at 12 months), 
$8,500/2.6 (reflex HPV16/18) and $7,278/2.6 (routine co-testing with 3-in-1 test). 
Using HPV16/18 genotyping to manage discordant co-testing results increased 
≥ CIN2 cases detected and prevented disease progression. Compared to other HPV 
tests that require reflex genotyping, screening with a 3-in-1 test reduced the cost 
of follow-up by 17% annually. ConClusions: Genotyping for HPV 16/18 improved 
the detection of ≥ CIN2 cases over repeat co-testing in 12 months; moreover, com-
pared to other HPV testing strategies, the 3-in-1 test reduced costs and may be a 
prudent screening alternative.
PIH8
eConomIC ImPaCt of tHe use of an aBsorBaBle adHesIon BarrIer In 
PreventIng adHesIons followIng oPen gyneCologIC surgerIes
Roy S.1, Carlton R.2, Clark R.S.2, Migliaccio-Walle K.2
1Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 2Xcenda, LLC, Palm Harbor, FL, 
USA
objeCtives: Abdominal adhesions are common after gynecologic surgeries, 
often resulting in complications such as bowel obstruction and chronic pain, 
which may lead to increased length of stay and more frequent readmissions. 
GYNECARE INTERCEED® Absorbable Adhesion Barrier is associated with fewer 
adhesion-related outcomes compared to surgeries without an adhesion-barrier. 
This analysis assesses the budget impact of GYNECARE INTERCEED® for reduc-
ing the incidence of postoperative adhesions in open surgical gynecologic pro-
cedures. Methods: A model was constructed to evaluate the budget impact to 
hospitals of adopting GYNECARE INTERCEED® for women undergoing open surgical 
gynecologic procedures. C-section surgery, hysterectomy, myomectomy, ovarian 
surgery, tubal surgery, and endometriosis surgery were modeled with and without 
the use of GYNECARE INTERCEED®. Incremental GYNECARE INTERCEED® material 
costs, medical costs arising from complications, and adhesion-related readmis-
sions were considered. GYNECARE INTERCEED® use was assumed in 50% of all 
procedures. Budget impact was reported over a 3-year period from a US hospital 
perspective (US$2013). Results: Assuming 100 gynecologic surgeries of each type 
and an average of one GYNECARE INTERCEED® sheet per surgery, a net savings 
of $439,975 with GYNECARE INTERCEED® over 3 years is estimated. GYNECARE 
INTERCEED® use resulted in 80 fewer patient cases developing adhesions. Although 
the use of GYNECARE INTERCEED® added $91,500 in material costs, this was com-
pletely offset by the reduction in complication costs ($230,766 savings) and fewer 
adhesion-related readmissions ($300,709 savings). By preventing adhesion-related 
complications, GYNECARE INTERCEED® prevented over 206 additional hospital days 
for patients. ConClusions: This analysis represents the first economic assess-
ment of GYNECARE INTERCEED® use in open gynecologic surgeries that incorpo-
rates the cost of the adhesion barrier, complications, and readmissions. Adoption 
of GYNECARE INTERCEED® absorbable adhesion barrier for appropriate gynecologic 
surgeries would likely result in significant savings for hospitals which would largely 
be driven by clinical patient benefits in terms of fewer complications and adhesion-
related readmissions.
PIH9
Budget ImPaCt of dIenogest In treatIng endometrIosIs assoCIated 
PelvIC PaIn In BrazIl: a PuBlIC PersPeCtIve analysIs
Ferracini M., Nakada C.P.
Bayer Healthcare Brazil, São Paulo, Brazil
objeCtives: Evaluate the budget impact to the public health care system in 
Brazil after introducing dienogest (2 mg) as a treatment option in detriment of 
GnRH analogues (GnRHa) for patients with endometriosis-associated pelvic pain 
(EAPP). Methods: The analysis was conducted from the public perspective over 
a five-year time horizon. The budget impact model (BIM) specifically considered 
comparison to UAE (pregnancies: 3.44, 95%CI 1.18- 10.03; live-births: 3.02, 95%CI 
1.00- 9.09). ConClusions: LUAO is less effective than UAE and MYO in the treat-
ment of symptomatic fibroids for women who want to preserve their uterus. The 
choice between UAE and MYO should be based on individuals’ short and long-
term expectations.
PIH3
meta-analysIs of BCg vaCCIne effICaCy for Infants In Ireland
Schmitz S.1, Usher C.2, Adams R.2, Kieran J.1, Barry M.2, Walsh C.1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland
objeCtives: BCG vaccination policy is greatly debated. An important issue for coun-
tries using the vaccine is to try and estimate any influence it has on the tuberculosis 
(TB) incidence in their population. The aim of this study is to estimate the effective-
ness of the BCG vaccine in infants in Ireland. Methods: We searched PubMed and 
Embase for studies assessing a relative reduction in TB events after vaccination 
in infants. Studies meeting relevant inclusion and exclusion criteria were sought. 
Observational data from Ireland was combined with raw data from studies identified 
in the literature in a random-effects meta-analysis model to estimate the relative 
risk (RR) of vaccine efficacy against pulmonary TB, extra-pulmonary TB (EPTB), TB 
meningitis and TB deaths. Results: Two meta-analyses were found. The first meta-
analysis reviewed identified 5 randomised control trials and 11 case control studies 
against pulmonary TB (Trials 0.26 95% CI 0.17, 0.38; Cases 0.48 95% CI 0.37, 0.62) 
and TB deaths (Trials 0.35 95% CI 0.14, 0.88). The second meta-analysis identified a 
further 7 case-control studies and evaluated BCG efficacy against EPTB (0.23 95%CI 
0.13, 0.42] and TB meningitis (0.27 95%CI 0.21, 0.33). Estimates from observational 
data from Ireland for pulmonary TB were (0.14, 95%CI 0.09, 0.20), EPTB (0.11, 95%CI 
0.05, 0.21), TB meningitis (0.17, 95%CI 0.04, 0.75) and TB deaths (0.13, 95%CI 0.00, 6.37). 
Pooled RR estimates from Irish data and international estimates show a significant 
reduction in TB cases: Pulmonary TB: 0.26 (95% CI: 0.13, 0.54), EPTB: 0.16 (95%CI: 
0.08, 0.34), TB meningitis: 0.27 (95%CI: 0.21, 0.34) and TB deaths: 0.33 (95%CI: 0.14, 
0.81). ConClusions: This meta-analysis of local observational data with interna-
tional trial data indicates that vaccination of infants with the BCG vaccine reduces 
the risk of pulmonary TB, EPTB, TB meningitis and TB deaths.
PIH4
Co-admInIstratIon of antIPsyCHotICs and antI-dementIa drugs In 
austrIa
Hinteregger M.1, Füzi J.2, Reichardt B.3
1Main Association of Austrian Social Security Institutions, Vienna, Austria, 2Sickness Fund 
Burgenland, Eisenstadt, Austria, 3Sickness Fund Burgenland, Eisenstadt, Burgenland, Austria
objeCtives: The use of antipsychotics for people with dementia is regarded as 
problematic, causing cerebrovascular side effects and increasing mortality. In 
some countries, health-policy makers have already addressed a need for action 
to reduce the prescription of antipsychotics in dementia. The main goal of the 
analysis is to determine the extent of co-medication of antipsychotics for patients 
with medically-treated dementia in Austria, stratified by age and sex. Methods: 
Provided in a pseudonymised manner, the data comprise all filled prescriptions of 
cholinesterase inhibitors and memantine in the years 2011 and 2012 at the expense 
of the 13 major Austrian health insurance funds, covering more than 97% of the 
Austrian population. Additionally, antipsychotic medication of the involved patient 
pseudonyms is included, as well as age, sex and – where occurred – date of death. 
For the analysis, the overlapping time frame is relevant, i.e. when both substance 
groups were consumed. Descriptive statistics are used to capture the extent and 
variability of a co-medication of these two substance groups. Results: Starting 
with 72,549 patients included in the data (66% female), 31,605 (43.6%) were concur-
rently being prescribed antipsychotics to their anti-dementia drugs. The median 
for the overlapping time frame is 294 days, for anti-dementia prescriptions it is 
eleven and for antipsychotics it is seven. Age is a factor for increasing antipsy-
chotic medication. Considering demography, there are no remarkable differences 
between men and women. ConClusions: Our data demonstrate that the use of 
antipsychotics in dementia is notably common in Austria, with a high prevalence 
as well as a tendency to long-term use. The results reflect the prescription reality 
and can be used as a solid basis for discussions, possible actions and evaluations 
about antipsychotics in dementia in the Austrian health system.
PIH6
assessIng ProduCt safety vIa PatIent Based aCtIve surveIllanCe (as): 
a study In 30.000 women usIng Hormone rePlaCement tHeraPy (Hrt)
Heinemann K.1, Bardenheuer K.1, Potthoff P.2
1ZEG-Berlin, Berlin, Germany, 2Kantar Health GmbH, München, Germany
objeCtives: The novel progestin drospirenone (DRSP) has antimineralocorticoid 
properties with potentially beneficial as well as unfavorable effects on cardiovas-
cular outcomes compared to other progestins. A patient based AS study was set 
up to compare incidence rates of serious adverse events – in particular cardiovas-
cular outcomes - in users of oral continuous combined preparations. Methods: 
Prospective, controlled cohort study (2002-2011) with three arms: women using 
1) DRSP/estradiol; 2) other oral continuous-combined HRT (occHRT); and 3) all 
other oral HRTs. The study population included women aged 40 or older in seven 
European countries starting or switching to an oral HRT at time of inclusion in the 
study. Outcomes were collected from the patients and validated by the treating 
physicians. A multifaceted 4-level follow-up procedure was to ensure low loss to 
follow-up rates. The analysis is based on Cox regression models comparing the 
cohorts. Results: A total of 30,597 users of oral HRT preparations – reflecting 
more than 101,000 WY of observation – were recruited by 1,052 centers. Incidence 
rates of DRSP/estradiol and low-dose occHRT for venous thromboembolic events 
were 17.5 (95% CI: 11.2-26.0) and 18.2 (95% CI: 11.9-26.6) per 10,000 WY, respectively. 
The respective incidence rates for arterial thromboembolism were 10.9 (95% CI: 
6.1-18.0) and 29.8 (95% CI: 24.1-36.4 ) per 10,000 WY with a hazard ratio adjusted 
for age, BMI, hypertension, region, family history of fatal ATE, diabetes, user status 
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objeCtives: Rotavirus (RV) is the most frequent cause of severe gastroenteritis fre-
quently requiring hospitalization. RV is responsible for > 1/2 of all hospital stays 
for acute gastroenteritis. The objective was to estimate the burden of community 
acquired rotavirus gastro-enteritis requiring hospitalization (CRVGE) in children ≤ 5 
years old in Czech Republic (CR) and Slovakia (SK). Methods: Multi-center, retro-
spective patient chart review was conducted in both pediatric and infection disease 
settings in CR (n= 109) and SK (n= 115). Resource use analysis including length of hos-
pital stay and tests performed were evaluated. Patients requiring rehydration, compli-
cations and comorbidities were considered. Direct cost from payer’s perspective were 
retrieved from official DRG lists (CR) and fixed hospitalization cost rates per case (SK). 
Micro-costing was done in parallel based on the resource use data. Results: Mean 
length of hospital stay in CR and SK was 3.9 (SD 1.9) and 4.1 days (SD 1.7) respectively. 
Prevalent diagnostic tests used were latex agglutination 44.0% (CR) and immunochro-
matography 92% (SK). Rehydration was required in 84.4% (CR) and 97% (SK) of cases. 
Comorbidities were reported in 24.8% (CR) and 27% (SK); complications in 10.1% (CR) 
and 7.8% (SK). The national list-based reimbursement per hospitalized CRVGE is € 
370-645 (CR) and € 561 (SK). The calculated average total costs, including treatment 
prior to, and after admission, were € 462 (CR) and € 583 (SK). The major cost item was 
the hospital stay with € 391 (CR) and € 540 (SK). Costs for tests and drugs during hos-
pitalization were € 30 (CR) and € 25 (SK). The costs of pre and post-hospitalization care 
were € 20 (CR) and € 13 (SK). ConClusions: Although the length of hospitalization 
in both countries is similar costs seem to be substantially lower in CR, possibly as a 
result of recently launched DRG system. Common complications and comorbidities 
account for 30% of average hospital costs.
PIH14
use of antenatal CortICosteroIds lowers HosPItalIzatIon Costs 
related to PrematurIty
Meneguel J.1, Fonseca M.2, Fonseca E.3, Almeida F.1, Grinsburg R.1
1UNIFESP, São Paulo, Brazil, 2Federal University of São Paulo / Axia.Bio Consulting, São Paulo, 
Brazil, 3Federal University of São Paulo, São Paulo, Brazil
objeCtives: According to WHO the use of antenatal corticosteroids (CEA) in pregnant 
women at risk of preterm birth < 34 weeks can prevent thousands of preterm neonates 
(PN) deaths. The impact of the use of CEA in hospital costs in developing countries is 
not known. Our objective was to compare morbidity and hospital costs of PN whose 
mothers received or not CEA. Methods: Analysis of PN medical records with gesta-
tional age 26-32 weeks born from Jan/2006-Dez/2009 in a tertiary, public and university 
hospital. We excluded infants with malformations. Maternal characteristics, hospital 
neonatal morbidity, use and doses of CEA and all used resources (tests, medications 
and procedures) were collected. Costs were estimated in Brazilian Reais, from the 
hospital perspective. Results: Of 211 PN, 170 received at least one dose of CEA to 6 
hours before delivery (G1) and 41 did not (G2). The groups had similar characteristics 
but G1 had more male infants (p < 0.05) and cesarean sections (p < 0,00). Morbidity: 
G2 needed more advanced resuscitation (16.5% vs 34%, p = 0.01), experienced more 
intraventricular hemorrhage III / IV (7.6% vs. 22%, p < 0.00) and retinopathy of pre-
maturity (12.4% vs. 24.4%, p = 0.05). Resource use: G1 consumed less mechanical 
ventilation days (5.3 vs 10.6, p = 0.04) and oxygen days (10.7 vs 17, p = 0.02); the num-
ber of NICU and Intermediate Care Nursery days were respectively (19.6 vs 27.5, p = 
0.07) and (24 vs 29.5 days, p = 0.14); there was no difference concerning use of CPAP 
(p = 0.07) and surfactant (p = 0.06). The average cost of hospitalization per patient 
was BRL 18,409 in G1 and BRL 24,090 in G2 (p = 0.03). ConClusions: The CEA is a 
simple measure, which helps to reduce PN morbidity and utilization of health care 
resources, reducing hospital costs.
PIH15
examInIng tHe Burden of Illness of tHe unIted states veteran 
PatIents dIagnosed wItH alzHeImer’s dIsease
Wang L.1, Xie L.2, Du J.2, Li L.1, Baser O.3
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
objeCtives: To examine the burden of illness of patients diagnosed with 
Alzheimer’s disease (AD) in the U.S. veteran population. Methods: A retrospective 
database analysis was performed using the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2008 through September 30, 2012. Patients 
diagnosed with AD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis code 331.0. The first diagnosis 
date was designated as the index date. A comparator group was created as well by 
identifying patients without an AD diagnosis but with the same age, region, gender, 
index year, and matching Charlson Comorbidity Index (CCI). The index date for 
the comparator group was randomly chosen to reduce the selection bias. A 1-year 
continuous health plan enrollment was required before and after the index date 
for both groups. One-to-one propensity score matching was used to compare the 
health care costs and utilizations during the follow-up period between the disease 
and comparator groups. Results: A total of 68,856 patients were included in the 
AD and comparison cohorts. After 1:1 matching, a total of 24,542 of patients were 
matched from each group, and the baseline characteristics were proportionate. The 
AD cohort had higher percentages of inpatient (18.46% vs. 2.06%, p< 0.01), emergency 
room (15.80% vs. 4.31%, p< 0.01), physician office (98.17% vs. 58.18%, p< 0.01), outpa-
tient (98.30% vs. 58.92, p< 0.01), and pharmacy visits (84.89% vs. 61.78%, p< 0.01). AD 
patients also incurred higher inpatient ($7,416 vs. $636, p< 0.01), emergency room 
($150 vs. $41, p< 0.01), physician office ($2,752 vs. $1,155, p< 0.01), outpatient visits 
($3,086 vs. $1,300) and pharmacy costs ($774 vs. $350, p< 0.01) compared to patients 
without AD. ConClusions: In this study, AD was associated with higher health 
care resource utilization and a significantly higher economic burden.
PIH17
a Cost of a CHIldBIrtH wItH In vItro fertIlIzatIon In Poland
Góra K., Hermanowski T., Wrona W.
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
women with EAPP. A recently cost-minimization (CM) model developed for EAPP 
provided the estimates of average treatment cost in Brazil based on local guidelines. 
This CM model compared different treatment pathways for women with EAPP and 
used a 50% improvement in pelvic pain as a definition of a treatment response. A 
patient flow was developed based on epidemiological and demographical data. 
Based on market uptake assumptions, results from the CM model and the patient 
flow, the BIM estimated the incremental budget impact after adopting dienogest. 
The model assumed that during the first year, 6.76% of EAPP patients receive dien-
ogest in detriment of GnRHa. After five years, it was assumed that dienogest would 
capture 30% of the GnRHa market in EAPP. Results: Based on the patient flow 
developed, approximately 0.52% of the population were estimated to be diagnosed 
with EAPP and receiving treatment with GnRHa. In the year after introduction of 
dienogest, the overall budget used to treat EAPP was estimated to decrease by 
up to 2.98% with the budget saving estimated to increase to around 12.98% by 
Year 5. ConClusions: This analysis portends that the budgetary impact of add-
ing dienogest to the public health care system in Brazil, in detriment of the GnRHa, 
result in a budgetary cost saving alternative.
PIH10
How muCH does BenIgn ProstatIC HyPerPlasIa Cost? a Budget ImPaCt 
analysIs on ItalIan PatIents treated wItH 5α -reduCtase InHIBItors
Povero M.1, Pitrelli A.2, Pradelli L.1
1AdRes HE&OR, Turin, Italy, 2GlaxoSmithKline, Verona, Italy
objeCtives: Second-line pharmacological therapy for benign prostatic hyperplasia 
(BPH) includes 5α -reductase inhibitors (5ARIs, dutasteride and finasteride). Aim of this 
study was the evaluation of the budget impact related to the variation in dutasteride 
and finasteride prescribing trends. Methods: Target population is the number of 
Italian BPH-patients, age ≥ 40 years, treated with dutasteride or finasteride. The BPH-
patients management was modeled on a dynamic cohort for 4-years. Epidemiological 
input data were elaborated from a observational study on pharmaceutical prescrip-
tion data of Italian BPH-patients; hospitalization rates were taken from a cohort study 
investigating BPH-related surgical and not surgical hospitalizations. Costs were cal-
culated as average of Italian DRGs weighted for BPH-related procedure frequency. 
Current Italian prescription shares of dutasteride and finasteride were compared 
with a 20% shift of prescriptions from dutasteride to finasteride (Scenario A) and 
a 20% shift of prescription from finasteride to dutasteride (Scenario B). Results: 
According to current prescribing trends, 372,078 hospitalizations for BPH are expected 
in 4 years. Mean annual cost for BPH-patients management results in 355 million € . 
Hospitalization cost is the main driver (228 milion € /year) while pharmacological ther-
apy accounts for 35% of the total cost (126 million Euro/year). Scenario A: additional 
11.485 hospitalizations related with BPH occur in 4 years; these lead to an increase in 
NHS cost only slightly offset by the savings in drugs acquisition cost: -0,08% savings 
on NHS budget (-0,28 milion € /year) Scenario B: the cost of drugs increases of 5% (+6 
million € /year) and prevents 9,920 hospitalizations in 4 years; the net budget impact 
of scenario B is +0,08% increase in cost (+0,27 milion € /year). ConClusions: The 
shift of prescription from dutasteride to finasteride leads to modest savings on NHS 
Budget while the shift from finasteride to dutasteride offsets the majority of increase 
in drug budget improving the outcome in patients.
PIH12
Costs of alternatIve metHods of CHIld delIvery In serBIa
Odalovic M.1, Lakic D.1, Tadic I.2, Tasic L.2, Petrova G.3
1University of Belgrade Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2University of 
Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3Medical University of Sofia, 
Sofia, Bulgaria
objeCtives: Different types of labour need different resources. Therefore, 
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist 
and to determine factors related to estimated costs. The costs of spontaneous labour 
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned 
C-section (CS) without labour were estimated. Methods: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance 
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical 
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of 
99 women were selected for the study sample; average age was 30.55±5.42 years. The 
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with 
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs. 
4.59±2.89 and 5.04±3.01 days, respectively, p< 0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p< 0.05) and 
5.14±3.39 (p> 0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery, 
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher 
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p< 0.05) and IVD (640.18±240.04 
vs. 497.10±327.91 EUR, p>0.05). ConClusions: The highest costs of labour in Serbia 
were costs of planned CS. Longer maternal/newborns hospital stay and more 
frequent hospitalization at semi-intensive and/or intensive care unites after CS 
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.
PIH13
Cost Burden of rotavIrus gastro-enterItIs requIrIng 
HosPItalIzatIons In tHe CzeCH rePuBlIC and In slovakIa
Vitova V.1, Mullerova J.2, Tichopad A.1, Dolezel J.3, Hlavinkova L.4, Pazdiora P.5,  
Stefkovicova M.6
1CEEOR s.r.o., Prague, Czech Republic, 2CEEOR Slovakia, Bratislava, Slovak Republic, 
3GlaxoSmithKline, Prague, Czech Republic, 4GlaxoSmithKline Slovakia, Bratislava, Slovak 
Republic, 5Charles University Hospital Pilsen, Plzen, Czech Republic, 6Regional Authority of Public 
Health, Trencin, Slovak Republic
